摘要:
Composition for pharmaceutical or cosmetic use, capable of forming a microemulsion, comprising at least:an active principle,a lipophilic phase consisting of a mixture of fatty acid esters and glycerides,a surfactant (SA),a cosurfactant (CoSA),a hydrophilic phase,characterized:in that the lipophilic phase consists of a mixture of C.sub.8 to C.sub.18 polyglycolized glycerides having a hydrophilic-lipophilic balance (HLB) of less than 16, this lipophilic phase representing from 30 to 75% of the total weight of the composition;in that the surfactant (SA) is chosen from the group comprising saturated C.sub.8 -C.sub.10 olyglycolized glycerides and oleic esters of polyglycerol, this surfactant having an HLB of less than 16;in that the cosurfactant (CoSA) is chosen from the group comprising lauric esters of propylene glycol, oleic esters of polyglycerol and ethyl diglycol;in that the SA/CoSA ratio is between 0.5 and 6;and in that the hydrophilic phase of the final microemulsion is supplied after ingestion by the physiological fluid of the digestive milieu.
摘要:
Composition for pharmaceutical or cosmetic use, capable of providing enhanced bioavailability when ingested, comprising at least a pharmaceutical active ingredient, a lipophilic phase consisting of a mixture of fatty acid esters and glycerides, a surfactant (SA), and a cosurfactant (CoSA). The lipophilic phase consists of a mixture of C8 to C18 polyglycolized glycerides having hydrophilic-lipophilic balance (HLB) of less than 16, this lipophilic phase representing from 32 to 75% of the total weight of the composition. The surfactant (SA) is chosen from the group comprising saturated C8-C10 polyglycolized glycerides and oleic esters of polyglycerol, this surfactant having an HLB of less than 16. The cosurfactant (CoSA) is chosen from the group comprising lauric esters of propylene glycol, oleic esters of polyglycerol and ethyl diglycol. The SA/CoSA ratio is between 0.5 and 6 and the hydrophilic phase of the final microemulsion is supplied after ingestion by the physiological fluid of the digestive milieu.
摘要翻译:用于药物或化妆品用途的组合物,其能够在摄入时提供增强的生物利用度,其包含至少一种药物活性成分,由脂肪酸酯和甘油酯的混合物组成的亲油相,表面活性剂(SA)和辅助表面活性剂(CoSA)。 亲油相由具有小于16的亲水亲油平衡(HLB)的C8至C18聚乙二醇化甘油酯的混合物组成,该亲油相占组合物总重量的32-75%。 表面活性剂(SA)选自饱和C8-C10聚乙二醇化甘油酯和聚甘油油酸酯的组,该表面活性剂的HLB小于16.辅助表面活性剂(CoSA)选自丙二醇月桂酸酯, 聚甘油和乙基二甘醇的油酸酯。 SA / CoSA比值在0.5和6之间,并且最终微乳液的亲水相由消化环境的生理液体摄取后供应。
摘要:
There is disclosed a process for improving a glycerolyzed oil. The oil is heated until any crystals which have formed have disappeared. Then the oil is crystallized by slow stirring for eight to seventy-two hours until an end of crystallization temperature of typically between 0.degree. and 15.degree. is reached. Finally the crystals which have formed are separated at the end of crystallization temperature. The process can be iterated at two successively lower end of crystallization temperatures.